Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "Facility"

1627 News Found

Briefs: Mankind Pharma and Sequent Scientific
News | September 26, 2023

Briefs: Mankind Pharma and Sequent Scientific

Mankind Pharma commences the commercial operations newly set-up plant in Udaipur


India becomes role model in crisis management and preventive healthcare: Dr. Jitendra Singh
News | September 25, 2023

India becomes role model in crisis management and preventive healthcare: Dr. Jitendra Singh

Dr. Jitendra Singh inaugurates 300 LPM capacity Oxygen Plant, Day Care Chemotherapy Unit affiliated to Tata Memorial Hospital & Maternal ICU at GMC Kathua


Strides receives USFDA approval for Icosapent Ethyl Capsules
Drug Approval | September 25, 2023

Strides receives USFDA approval for Icosapent Ethyl Capsules

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)


Natural Biogenex performs inauguration at Tumkur unit
News | September 22, 2023

Natural Biogenex performs inauguration at Tumkur unit

This production block consists of chemical synthesis reactions and clean rooms areas to produce final API


Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%
Drug Approval | September 21, 2023

Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Clindamycin Phosphate Gel is used to treat acne


Briefs: Caplin Steriles, Zydus  and APL Healthcare
Drug Approval | September 20, 2023

Briefs: Caplin Steriles, Zydus and APL Healthcare

Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients


RML Hospital inaugurates India’s first dedicated OPD for transgenders
News | September 18, 2023

RML Hospital inaugurates India’s first dedicated OPD for transgenders

Free Treatment, investigations and sex change surgery along with other facilities will be available at these OPDs for the Transgender community


Strides receives tentative USFDA approval for Dolutegravir/Lamivudine/Tenofovir Disproxil Fumurate tablets
Drug Approval | September 16, 2023

Strides receives tentative USFDA approval for Dolutegravir/Lamivudine/Tenofovir Disproxil Fumurate tablets

Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa


Zydus receives final approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System
Drug Approval | September 16, 2023

Zydus receives final approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System

Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States


Strides receives tentative USFDA approval for Dolutegravir tablets
Drug Approval | September 15, 2023

Strides receives tentative USFDA approval for Dolutegravir tablets

The products will be manufactured at the company's facility in Bengaluru